Evidence map›Paper›PMID 40949255›Full record

ArticleACS omega2025

Harnessing Lignin-Derived Carbon Dots for Enhanced NIR Photothermal Ablation of Melanoma Cells.

Vinita Satwani, Badri Narayana Sahoo, Kallayi Nabeela, Abhijeet Joshi, Shaikh M Mobin

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vinita SatwaniDepartment of Chemistry, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore, Madhya Pradesh 453552, India.
Badri Narayana SahooDepartment of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore, Madhya Pradesh 453552, India.
Kallayi NabeelaDepartment of Chemistry, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore, Madhya Pradesh 453552, India.
Abhijeet JoshiDepartment of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore, Madhya Pradesh 453552, India.ORCID https://orcid.org/0000-0002-7035-0001
Shaikh M MobinDepartment of Chemistry, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore, Madhya Pradesh 453552, India.ORCID https://orcid.org/0000-0003-1940-3822

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integration of optical imaging modalities with photothermal therapy (PTT) enables simultaneous oncotherapy and bioimaging, offering improved therapeutic efficacy and enhanced treatment precision. As a result, this approach has emerged as a promising strategy for cancer treatment. Carbon dots (CDs) are highly stable, biocompatible materials with exceptional fluorescent properties, making them strong contenders for optical bioimaging and photothermal applications. However, challenges remain in synthesizing optimal CDs due to insufficient photothermal conversion efficiency, often requiring high laser power densities and higher CD concentrations for effective photothermal therapy (PTT). In this study, nitrogen-doped lignin-derived CDs (N-LCDs) are synthesized via a green, low-cost route using lignin as the carbon source and ethylenediamine as the nitrogen dopant. The resulting N-LCDs exhibit excellent absorption in the near-infrared (NIR) range, superior photothermal stability, and remarkable biocompatibility. Cellular uptake studies confirmed efficient internalization, while flow cytometry analysis revealed significant apoptosis upon NIR laser exposure, validating their photothermal therapeutic effect. The structural and optical characterization of N-LCDs demonstrates a high photothermal conversion efficiency (PCE ∼ 57.5%), highlighting their potential as effective and safe bioimaging and photothermal agents for in vitro cancer therapy.

Identifiers

PMID40949255
PMCPMC12423852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.